Shaigan Pharmaceuticals (Pvt) Ltd
Private pharmaceutical manufacturer · Rawalpindi · Pakistan
Rawalpindi-based pharmaceutical manufacturer focused on branded generic medicines, quality systems and international market expansion.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Shaigan Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 14-km, Adyala Road, Post Office Dahgal, Rawalpindi, Pakistan
- Website
- shaigan.com ↗
- Phone
- +92 51 5133060-8
- info@shaigan.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Ruwin | Cefixime | 200 mg/5 mL | Dry suspension | 30 ml | 075355 | PKR 404.32 | PKR 13.48/mL | Near median |
| Ruwin | Cefixime | 400 mg | Capsule | 5x10's | 090286 | PKR 5,000.18 | PKR 100.00/capsule | 11% below median |
| Ruwin | Cefixime | 400 mg | Capsule | 2x5's | 090286 | PKR 1,136.71 | PKR 113.67/capsule | Near median |
| Ruwin | Cefixime | 400 mg | Capsule | 5's | 090286 | PKR 592.04 | PKR 118.41/capsule | Near median |
| Ruwin | Cefixime | 200 mg | Capsule | 1 x 5's | 097601 | PKR 366.69 | PKR 73.34/capsule | 17% above median |
| Shai-C | Ascorbic acid | 500 mg | Chewable tablet | 40's | 103369 | PKR 55.40 | PKR 1.39/tablet | Near median |
| Skab | Permethrin | 5% w/w | Cream | 90gm | 051099 | PKR 275.90 | PKR 3.07/g | 25% below median |
| Skab | Permethrin | 50 mg/g | Cream | 60gm | 051099 | PKR 187.77 | PKR 3.13/g | 11% below median |
| Skab | Permethrin | 5% w/w | Cream | 30gm | 051099 | PKR 122.76 | PKR 4.09/g | 31% above median |
| Skab | Permethrin | 5% w/w | Cream | 40gm | 051099 | PKR 125.17 | PKR 3.13/g | 24% below median |
| Skab | Permethrin | 50 mg | Lotion | 120ml | 051197 | PKR 327.57 | PKR 2.73/mL | Near median |
| Skab | Permethrin | 50 mg/g | Cream | 90ml | 051197 | PKR 250.80 | PKR 2.79/mL | Near median |
| Skab | Permethrin | 50 mg/g | Cream | 60ml | 051197 | PKR 170.62 | PKR 2.84/mL | Near median |
| Solone | Prednisolone | 1 % | Suspension | 5mlx1's | 083593 | PKR 105.99 | PKR 21.20/mL | No comparator |
| Sporay | Itraconazole | 100 mg | Capsule | 4's | 051174 | PKR 648.67 | PKR 162.17/capsule | 12% above median |
| Sterile WFI | Water for Injection | 10 mL | Injection | 1x10ml | 035535 | PKR 23.95 | PKR 2.40/mL | 18% above median |
| Sterile WFI | Water for Injection | 2 mL | Injection | 1x2ml | 035535 | PKR 5.24 | PKR 2.62/mL | 9% above median |
| Sterile WFI | Water for Injection | 5 mL | Injection | 1x5ml | 035535 | PKR 7.86 | PKR 1.57/mL | 22% below median |
| Sygate | Conjugated estrogens | 0.625 mg | Tablet | 2x10's | 083592 | PKR 94.40 | PKR 4.72/tablet | 5% below median |
| Sygate | Conjugated estrogens | 0.3 mg | Tablet | 30's | 083597 | PKR 111.57 | PKR 3.72/tablet | 90% below median |
| Sygate | Conjugated estrogens | 1.25 mg | Tablet | 10x2's | 083600 | PKR 152.63 | PKR 7.63/tablet | No comparator |
| Temprin | Artemether + Lumefantrine | 240 mg + 240 mg | Tablet | 8's | 075356 | PKR 563.04 | PKR 70.38/tablet | 8% above median |
| Temprin | Artemether + Lumefantrine | 240 mg + 240 mg | Tablet | 6x8's | 075356 | PKR 2,853.08 | PKR 59.44/tablet | 11% below median |
| Temprin | Artemether + Lumefantrine | 20 mg + 120 mg | Tablet | 2x8 | 085372 | PKR 542.56 | PKR 33.91/tablet | 15% below median |
| Temprin Plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 6's | 075357 | PKR 703.80 | PKR 117.30/tablet | 8% above median |
| Temprin Plus | Artemether + Lumefantrine | 80 mg + 480 mg | Tablet | 4's | 075357 | PKR 469.20 | PKR 117.30/tablet | 8% above median |
| Ternifer | Terbinafine | 1 % | Cream | 10gm | 109369 | PKR 237.33 | PKR 23.73/g | 19% below median |
| Ternifer | Terbinafine | 1 % | Gel | 10gm | 109370 | PKR 237.33 | PKR 23.73/g | 20% above median |
| Ticavir | Entecavir | 0.5 mg | Tablet | 3x10's | 063199 | PKR 18,844.91 | PKR 628.16/tablet | 76% above median |
| Ticavir | Entecavir | 1 mg | Tablet | 30's | 072007 | PKR 22,613.82 | PKR 753.79/tablet | 31% above median |
| Trozet | Letrozole | 2.5 mg | Tablet | 30's | 090087 | PKR 14,094.71 | PKR 469.82/tablet | 17% above median |
| Trozet | Letrozole | 2.5 mg | Tablet | 1's | 090087 | PKR 469.82 | PKR 469.82/tablet | 17% above median |
| Trozet | Letrozole | 2.5 mg | Tablet | 1x10's | 090087 | PKR 4,510.30 | PKR 451.03/tablet | 12% above median |
| Vebuvir | Sofosbuvir | 400 mg | Tablet | 28's | 094329 | PKR 11,704.88 | PKR 418.03/tablet | Near median |
| Vebuvir-L 400mg | Sofosbuvir | 400 mg | Tablet | 28's | 099566 | PKR 54,289.61 | PKR 1,938.91/tablet | 354% above median |
| Vebvel | Sofosbuvir | 400 mg | Tablet | 28's | 102333 | PKR 18,465.85 | PKR 659.49/tablet | 55% above median |
| Vyber | Omeprazole | 40 mg | Lyophilized powder for injection | 1's | 069894 | PKR 619.59 | PKR 619.59/vial/unit | Near median |
| Vyber | Omeprazole | 40 mg | Capsule | 14's | 098308 | PKR 485.38 | PKR 34.67/capsule | Near median |
| Vyber | Omeprazole | 20 mg | Capsule | 14's | 098309 | PKR 279.58 | PKR 19.97/capsule | Near median |
| Warfin | Warfarin | 5 mg | Tablet | 3x10'x | 018670 | PKR 467.94 | — | No comparator |
| Warfin | Warfarin | 5 mg | Tablet | 100's | 018670 | PKR 1,559.80 | PKR 15.60/tablet | 24% above median |
| Warfin | Warfarin | 1 mg | Tablet | 10x10's | 063194 | PKR 480.01 | PKR 4.80/tablet | 11% above median |
| Warfin | Warfarin | 2.5 mg | Tablet | 10x10's | 063195 | PKR 778.41 | PKR 7.78/tablet | Near median |
| Water for | Water for Injection | 1 mL | Injection | 1ml | 084352 | PKR 4.12 | PKR 4.12/mL | 11% below median |
| Wetrex | Furosemide | 50 mg | Tablet | 20's | 096497 | PKR 118.93 | PKR 5.95/tablet | No comparator |
| Wolide | Linezolid | 600 mg | Tablet | 12's | 101807 | PKR 1,974.00 | PKR 164.50/tablet | 58% below median |
| WolideSource observed | — | 100 mg/5 mL | Suspension | 60ml | 119674Official source ↗ | No indexed price | — | — |
| Wolide | Linezolid | 400 mg | Tablet | 12's | 124578 | PKR 1,580.23 | PKR 131.69/tablet | 44% below median |
| Xepil | Carbamazepine | 200 mg | Tablet | 50's | 018673 | PKR 340.78 | PKR 6.82/tablet | 37% below median |
| Zedron | Ondansetron | 2 mg/4 mL | Injection | 4mlx5's | 042573 | PKR 5,228.20 | PKR 261.41/mL | No comparator |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.